Edition:
United Kingdom

Rockwell Medical Inc (RMTI.OQ)

RMTI.OQ on NASDAQ Stock Exchange Global Market

6.48USD
14 Dec 2017
Change (% chg)

$0.37 (+6.06%)
Prev Close
$6.11
Open
$6.12
Day's High
$6.78
Day's Low
$6.09
Volume
157,738
Avg. Vol
66,198
52-wk High
$8.97
52-wk Low
$5.07

Latest Key Developments (Source: Significant Developments)

Rockwell Medical Signs License Agreement With Quimica Europea To Commercialize Triferic In Peru
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Rockwell Medical Inc ::ROCKWELL MEDICAL SIGNS EXCLUSIVE LICENSE AGREEMENT WITH QUIMICA EUROPEA TO COMMERCIALIZE TRIFERIC IN PERU.ROCKWELL MEDICAL - SIGNED LICENSE & MANUFACTURING SUPPLY DEAL WITH QUIMICA EUROPEA FOR RIGHTS TO COMMERCIALIZE TRIFERIC FOR ESRD PATIENTS IN PERU.ROCKWELL MEDICAL INC- QUIMICA EUROPEA WILL BECOME EXCLUSIVE DISTRIBUTOR FOR TRIFERIC IN PERU FOR AN INITIAL COMMERCIAL TERM OF FIVE YEARS.ROCKWELL MEDICAL INC - ROCKWELL RETAINS MANUFACTURING RESPONSIBILITY OF ALL PRODUCTS.ROCKWELL MEDICAL- QUIMICA TO ASSUME ALL REGULATORY RESPONSIBILITIES,RELATED EXPENSES IN OBTAINING GOVERNMENT COMMERCIAL MARKETING APPROVAL FOR TRIFERIC.  Full Article

Richmond Brothers Says On Nov 22, Entered Into Settlement And Standstill Agreement With Rockwell Medical
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Rockwell Medical Inc ::RICHMOND BROTHERS INC​ SAYS ON NOVEMBER 22, ENTERED INTO SETTLEMENT AND STANDSTILL AGREEMENT WITH ROCKWELL MEDICAL INC - SEC FILING.RICHMOND BROTHERS-PURSUANT TO SETTLEMENT,STANDSTILL AGREEMENT, ROCKWELL MEDICAL AGREED TO APPOINT, ONE ADDITIONAL MEMBER TO BOARD NO LATER THAN FEB 15, 2018.RICHMOND BROTHERS - STANDSTILL PERIOD SHALL TERMINATE ON FEB 15, 2018 IN EVENT THAT ADDITIONAL DIRECTOR NOT APPOINTED TO BOARD PRIOR TO FEB 15, 2018.RICHMOND BROTHERS - DURING STANDSTILL PERIOD, RICHMOND PARTIES AGREED NOT TO ACQUIRE OVER MORE THAN 12% OF ROCKWELL MEDICAL'S OUTSTANDING SHARES.  Full Article

Rockwell Medical posts Q3 loss of $0.10 per share
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Rockwell Medical Inc :Rockwell medical reports third quarter results.Q3 loss per share $0.10.Q3 sales rose 14.1 percent to $14.6 million.  Full Article

ROCKWELL MEDICAL SAYS FDA REQUESTS EXTRA TIME TO REVIEW CALCITRIOL SUBMISSION
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Rockwell Medical Inc ::ROCKWELL UPDATE ON CALCITRIOL POST-APPROVAL MANUFACTURING SUBMISSION TO FDA.ROCKWELL MEDICAL INC - ‍FDA HAS REQUESTED EXTRA TIME TO REVIEW ITS POST-APPROVAL DRUG MANUFACTURING SUBMISSION THAT WAS FILED WITH FDA SEPTEMBER 28.‍FDA WAS REQUIRED TO PROVIDE ROCKWELL WITH A DETERMINATION ON ITS SEPTEMBER 28(TH) SUBMISSION WITHIN 30 DAYS​.ROCKWELL MEDICAL INC - ‍ROCKWELL INTENDS TO SELL CALCITRIOL COMMERCIALLY ONCE FDA APPROVES ITS POST-APPROVAL DRUG MANUFACTURING SUBMISSION​.‍COMPANY EXPECTS TO HAVE AN ANSWER FROM FDA IN APPROXIMATELY FOUR MONTHS​.  Full Article

Rockwell Medical enters into license agreement with ARAM Medical
Tuesday, 16 Aug 2016 

Rockwell Medical Inc: Rockwell Medical enters into exclusive license agreement with ARAM Medical to commercialize Triferic® in Saudi Arabia, Egypt and Middle East territories . ARAM will also assume responsibility for all clinical and regulatory expenses for territories . Rockwell retains manufacturing responsibilities for both Triferic and Calcitriol . Commercial product availability expected within about 12 months in Saudi Arabia and 12 to 18 months in Egypt and all other territories . ARAM medical will become exclusive distributor for Triferic and Calcitriol in 13 countries .ARAM will pay to Rockwell upfront licensing fees, a "high double-digit royalty on product sales".  Full Article

Rockwell Medical Inc - qtrly sales were $13.5 mln, or 3.8% higher than Q2 2015
Monday, 8 Aug 2016 

Rockwell Medical Inc :Qtrly sales were $13.5 million, or 3.8% higher than q2 2015..  Full Article

Rockwell Medical Q1 loss per share $0.10
Tuesday, 10 May 2016 

Rockwell Medical Inc : Rockwell Medical reports first quarter results . Qtrly net loss $0.10 per share . Q1 earnings per share view $-0.08, revenue view $15.2 million -- Thomson Reuters I/B/E/S . Q1 loss per share $0.10 .Q1 sales $13.6 million versus $13.9 million.  Full Article

Rockwell Medical enters into license agreement with Wanbang Biopharmaceutical Co., Ltd. to commercialize Triferic® in China
Tuesday, 16 Feb 2016 

Rockwell Medical Inc:Rockwell Medical enters into exclusive license agreement with wanbang biopharmaceutical co., ltd. to commercialize triferic® in China.Wanbang will become the exclusive distributor for triferic and calcitriol in China for an initial commercial term of 10 years.Agreements with wanbang biopharmaceutical for rights to commercialize triferic and calcitriol for end-stage-renal-disease patients.Will receive from wanbang an upfront fee plus regulatory and revenue milestone payments totaling USD$39 million in aggregate.Rockwell will receive ongoing earnings from product sales of triferic,calcitriol, other additional triferic therapeutic indications.  Full Article

BRIEF-Rockwell Medical Signs Exclusive License Agreement With Comercializadora BioRenal SpA

* ROCKWELL MEDICAL SIGNS EXCLUSIVE LICENSE AGREEMENT WITH COMERCIALIZADORA BIORENAL SPA TO COMMERCIALIZE TRIFERIC® IN CHILE